Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Interpreting test results: don't blame the tools.

Sundar S.

BMJ. 2020 Mar 25;368:m1162. doi: 10.1136/bmj.m1162. No abstract available.

PMID:
32213485
2.

Plain English is neither simple nor easy.

Sundar S.

BMJ. 2020 Mar 11;368:m949. doi: 10.1136/bmj.m949. No abstract available.

PMID:
32161003
3.

Prostate cancer: trial data meet the real world.

Sundar S.

BMJ. 2020 Feb 12;368:m519. doi: 10.1136/bmj.m519. No abstract available.

PMID:
32051122
4.

Call-out culture demands perfection from everyone except oneself.

Sundar S.

BMJ. 2020 Jan 20;368:m158. doi: 10.1136/bmj.m158. No abstract available.

PMID:
31959696
5.

Prognosis of early stage small cell bladder cancer is not always dismal.

Lim JH, Sundar S.

ESMO Open. 2019 Nov 13;4(6):e000559. doi: 10.1136/esmoopen-2019-000559. eCollection 2019.

6.

Treating sepsis in dying patients is futile.

Sundar S.

BMJ. 2019 Dec 2;367:l6706. doi: 10.1136/bmj.l6706. No abstract available.

PMID:
31792100
7.

Late cancer diagnoses: biology triumphs clinical acumen.

Sundar S.

BMJ. 2019 Aug 18;366:l5155. doi: 10.1136/bmj.l5155. No abstract available.

PMID:
31427283
8.

Banning free speech is counterproductive.

Sundar S.

BMJ. 2019 Jul 16;366:l4626. doi: 10.1136/bmj.l4626. No abstract available.

PMID:
31311784
9.

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.

Woods BS, Sideris E, Sydes MR, Gannon MR, Parmar MKB, Alzouebi M, Attard G, Birtle AJ, Brock S, Cathomas R, Chakraborti PR, Cook A, Cross WR, Dearnaley DP, Gale J, Gibbs S, Graham JD, Hughes R, Jones RJ, Laing R, Mason MD, Matheson D, McLaren DB, Millman R, O'Sullivan JM, Parikh O, Parker CC, Peedell C, Protheroe A, Ritchie AWS, Robinson A, Russell JM, Simms MS, Srihari NN, Srinivasan R, Staffurth JN, Sundar S, Thalmann GN, Tolan S, Tran ATH, Tsang D, Wagstaff J, James ND, Sculpher MJ.

Eur Urol Oncol. 2018 Dec;1(6):449-458. doi: 10.1016/j.euo.2018.06.004. Epub 2018 Sep 14.

10.

High sensitivity troponin assays: too much of a good thing.

Sundar S.

BMJ. 2019 Apr 16;365:l1640. doi: 10.1136/bmj.l1640. No abstract available.

PMID:
30992262
11.

Palliative care: relocation rather than rebranding is needed.

Sundar S.

BMJ. 2019 Apr 10;365:l1641. doi: 10.1136/bmj.l1641. No abstract available.

PMID:
30971413
12.

Renaming low risk cancers: honest engagement with patients is more important.

Sundar S.

BMJ. 2019 Feb 26;364:l840. doi: 10.1136/bmj.l840. No abstract available.

PMID:
30808719
13.

Categorising severity of disease is inevitable and essential in routine medical practice.

Sundar S.

BMJ. 2018 Jun 14;361:k2556. doi: 10.1136/bmj.k2556. No abstract available.

PMID:
29903848
14.

Understanding cardiopulmonary resuscitation.

Masters BJ, Mandeir J, O'Shaughnessy J, Sundar S.

J Pediatr. 2017 Nov;190:291-292. doi: 10.1016/j.jpeds.2017.07.031. No abstract available.

PMID:
29144260
15.

Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.

Jones RJ, Hussain SA, Protheroe AS, Birtle A, Chakraborti P, Huddart RA, Jagdev S, Bahl A, Stockdale A, Sundar S, Crabb SJ, Dixon-Hughes J, Alexander L, Morris A, Kelly C, Stobo J, Paul J, Powles T.

J Clin Oncol. 2017 Jun 1;35(16):1770-1777. doi: 10.1200/JCO.2016.70.7828. Epub 2017 Apr 12.

PMID:
28402747
16.

Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.

Powles T, Huddart RA, Elliott T, Sarker SJ, Ackerman C, Jones R, Hussain S, Crabb S, Jagdev S, Chester J, Hilman S, Beresford M, Macdonald G, Santhanam S, Frew JA, Stockdale A, Hughes S, Berney D, Chowdhury S.

J Clin Oncol. 2017 Jan;35(1):48-55. Epub 2016 Oct 28.

PMID:
28034079
17.

Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.

Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PM, Sundar S, van der Steen-Banasik EM, Armstrong J, Bosset JF, Herrera FG, Pieters B, Slot A, Bahl A, Ben-Yosef R, Boehmer D, Scrase C, Renard L, Shash E, Coens C, van den Bergh AC, Collette L.

J Clin Oncol. 2016 May 20;34(15):1748-56. doi: 10.1200/JCO.2015.64.8055. Epub 2016 Mar 14.

PMID:
26976418
18.

Resuscitation is futile in terminally ill patients.

Sundar S.

BMJ. 2016 Feb 10;352:i598. doi: 10.1136/bmj.i598. No abstract available.

PMID:
26864242
19.

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators.

Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21.

20.

Neutrophil-lymphocyte ratio is prognostic but not predictive of response to Abiraterone in metastatic castration-resistant prostate cancer.

Sundar S, O'Cathail M.

JRSM Open. 2015 Nov 3;6(12):2054270415611332. doi: 10.1177/2054270415611332. eCollection 2015 Dec. No abstract available.

21.

Degree of Rectal Distension Seen on Prostate Radiotherapy Planning CT Scan Is Not a Negative Prognostic Factor in the Modern Era of Image-Guided Radiotherapy.

Silverman R, Johnson K, Perry C, Sundar S.

Oncology. 2016;90(1):51-6. doi: 10.1159/000441225. Epub 2015 Nov 6.

PMID:
26540171
22.

Geographical tongue induced by axitinib.

Sundar S, Burge F.

BMJ Case Rep. 2015 Oct 16;2015. pii: bcr2015211318. doi: 10.1136/bcr-2015-211318. No abstract available.

23.

A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.

Powles T, Wheater M, Din O, Geldart T, Boleti E, Stockdale A, Sundar S, Robinson A, Ahmed I, Wimalasingham A, Burke W, Sarker SJ, Hussain S, Ralph C.

Eur Urol. 2016 Mar;69(3):450-6. doi: 10.1016/j.eururo.2015.08.035. Epub 2015 Sep 11.

PMID:
26364551
24.

A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer.

Hoskin P, Sundar S, Reczko K, Forsyth S, Mithal N, Sizer B, Bloomfield D, Upadhyay S, Wilson P, Kirkwood A, Stratford M, Jitlal M, Hackshaw A.

J Natl Cancer Inst. 2015 Aug 4;107(10). pii: djv197. doi: 10.1093/jnci/djv197. Print 2015 Oct.

PMID:
26242893
25.

Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients.

Pasquier D, Barney B, Sundar S, Poortmans P, Villa S, Nasrallah H, Boujelbene N, Ghadjar P, Lassen-Ramshad Y, Senkus E, Oar A, Roelandts M, Amichetti M, Vees H, Zilli T, Ozsahin M.

Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):904-10. doi: 10.1016/j.ijrobp.2015.03.019. Epub 2015 Mar 25.

PMID:
26104942
26.

New law on consent will overload seriously ill patients.

Sundar S.

BMJ. 2015 Apr 7;350:h1787. doi: 10.1136/bmj.h1787. No abstract available.

PMID:
25851299
27.

RE: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.

Adhikaree J, Newby Y, Sundar S.

J Natl Cancer Inst. 2015 Feb 6;107(3). pii: dju509. doi: 10.1093/jnci/dju509. Print 2015 Mar. No abstract available.

PMID:
25663690
28.

Clinical surgical trials need to be encouraged.

Sundar S.

BMJ. 2015 Jan 20;350:h282. doi: 10.1136/bmj.h282. No abstract available.

PMID:
25647170
29.

Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).

Bahl A, Masson S, Malik Z, Birtle AJ, Sundar S, Jones RJ, James ND, Mason MD, Kumar S, Bottomley D, Lydon A, Chowdhury S, Wylie J, de Bono JS.

BJU Int. 2015 Dec;116(6):880-7. doi: 10.1111/bju.13069. Epub 2015 Jun 16.

30.
31.

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.

Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, de Santis M, Théodore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R; European Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group; Groupe d'Etude des Tumeurs Urogénitales; National Cancer Research Institute Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; German Association of Urologic Oncology.

Lancet Oncol. 2015 Jan;16(1):76-86. doi: 10.1016/S1470-2045(14)71160-X. Epub 2014 Dec 11.

PMID:
25498218
32.

Misconceptions about 'do-not-resuscitate (DNR)' orders in the era of social media.

Sundar S, Do J, O'Cathail M.

Resuscitation. 2015 Jan;86:e3. doi: 10.1016/j.resuscitation.2014.10.014. Epub 2014 Oct 30. No abstract available.

PMID:
25447430
33.

Milk and mortality: the potential effects of modern milk production.

Sundar S.

BMJ. 2014 Nov 26;349:g7006. doi: 10.1136/bmj.g7006. No abstract available.

PMID:
25427769
34.

"Saatchi bill": legal hurdles and clinical irrelevance.

Sundar S.

BMJ. 2014 May 14;348:g3146. doi: 10.1136/bmj.g3146. No abstract available.

PMID:
25134109
35.

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR; CA184-043 Investigators.

Lancet Oncol. 2014 Jun;15(7):700-12. doi: 10.1016/S1470-2045(14)70189-5. Epub 2014 May 13.

36.

Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.

Adhikaree J, Newby Y, Sundar S.

BMJ Case Rep. 2014 Jan 30;2014. pii: bcr2013202861. doi: 10.1136/bcr-2013-202861.

37.

Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancer.

Malik Z, Payne H, Ansari J, Chowdhury S, Butt M, Birtle A, Sundar S, Eswar CV, Hughes S, Bahl A.

Adv Ther. 2013 Dec;30(12):1041-66. doi: 10.1007/s12325-013-0070-z. Epub 2013 Nov 26. Review.

PMID:
24276853
38.

Claims about NHS deficiencies without robust data undermine trust.

Sundar S.

BMJ. 2013 Oct 15;347:f6158. doi: 10.1136/bmj.f6158. No abstract available.

PMID:
24129380
39.

Patients with cancer say yes to palliative chemotherapy.

Sundar S.

BMJ. 2013 Jul 23;347:f4647. doi: 10.1136/bmj.f4647. No abstract available.

PMID:
23881996
40.

Some forms of knowledge are more equal than others.

Sundar S.

BMJ. 2012 Nov 6;345:e7429. doi: 10.1136/bmj.e7429. No abstract available.

PMID:
23132091
41.

The return of the snake oil salesmen: the sequel.

Sundar S.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):571. doi: 10.1016/j.ijrobp.2012.06.016. No abstract available.

PMID:
22999270
42.

Salvage radiotherapy after high intensity focused ultrasound for prostate cancer.

Dickinson P, Sundar S.

BMJ Case Rep. 2012 Jun 8;2012. pii: bcr0320126127. doi: 10.1136/bcr.03.2012.6127.

43.

Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate.

Sundar S, Dickinson PD.

BMJ Case Rep. 2012 Feb 25;2012. pii: bcr1120115238. doi: 10.1136/bcr.11.2011.5238.

44.

Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.

Perry CJ, Sundar S.

Clin Genitourin Cancer. 2012 Sep;10(3):207-9. doi: 10.1016/j.clgc.2012.01.011. Epub 2012 Mar 23. No abstract available.

PMID:
22445962
45.
46.

Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?

Ho JW, Sundar S.

Clin Genitourin Cancer. 2012 Mar;10(1):50-3. doi: 10.1016/j.clgc.2011.11.004. Epub 2012 Jan 14. No abstract available.

PMID:
22245101
47.

A self-adaptive case-based reasoning system for dose planning in prostate cancer radiotherapy.

Mishra N, Petrovic S, Sundar S.

Med Phys. 2011 Dec;38(12):6528-38. doi: 10.1118/1.3660517.

PMID:
22149835
48.

Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU Guidelines. Eur Urol 2011;59:1009-18.

Sundar S.

Eur Urol. 2011 Dec;60(6):e51. doi: 10.1016/j.eururo.2011.08.079. Epub 2011 Sep 17. No abstract available.

PMID:
21943777
49.

Management of endocrine resistant breast cancer.

Sundar S, Decatris MP, O'Byrne KJ.

J Br Menopause Soc. 2004 Mar;10(1):16-23. Review.

PMID:
15107207
50.

International register of trial acronyms.

Sundar S, Lawton P.

Lancet. 2004 Jan 10;363(9403):171. No abstract available.

PMID:
14726188

Supplemental Content

Loading ...
Support Center